RCM
RA Capital Management Portfolio holdings
AUM
$5.94B
This Quarter Return
+26.28%
1 Year Return
+18.15%
3 Year Return
+417.5%
5 Year Return
+458.13%
10 Year Return
+21,247.51%
AUM
$616M
AUM Growth
–
Cap. Flow
+$616M
Cap. Flow
% of AUM
99.96%
Top 10 Holdings %
Top 10 Hldgs %
75.13%
Holding
25
New
24
Increased
–
Reduced
–
Closed
–
Top Buys
| 1 |
Acadia Pharmaceuticals
ACAD
|
$119M |
| 2 |
ACHN
Achillion Pharmaceuticals, Inc.
ACHN
|
$61M |
| 3 |
KERX
Keryx Biopharmaceuticals Inc
KERX
|
$42.3M |
| 4 |
Sangamo Therapeutics
SGMO
|
$41.9M |
| 5 |
DYAX
DYAX CORPORATION
DYAX
|
$37.7M |
Top Sells
No sells this quarter
Sector Composition
| 1 | Healthcare | 87.26% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Acadia Pharmaceuticals
ACAD
$4.38B
| $119M | 15.72% | +6,529,810 | New | +$119M |
|
|
ACHN
2
DELISTED
Achillion Pharmaceuticals, Inc.
ACHN
| $61M | 8.09% | +7,455,202 | New | +$61M |
|
|
KERX
3
DELISTED
Keryx Biopharmaceuticals Inc
KERX
| $42.3M | 5.61% | +5,659,285 | New | +$42.3M |
|
|
4
Sangamo Therapeutics
SGMO
$157M
| $41.9M | 5.56% | +5,368,094 | New | +$41.9M |
|
|
DYAX
5
DELISTED
DYAX CORPORATION
DYAX
| $37.7M | 5.01% | +10,908,379 | New | +$37.7M |
|
|
LUMO
6
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
| $36.3M | 4.81% | +1,840,294 | New | +$36.3M |
|
7
Novavax
NVAX
$1.21B
| $35.2M | 4.67% | +17,170,801 | New | +$35.2M |
|
8
TherapeuticsMD
TXMD
$12.8M
| $34.1M | 4.53% | +11,262,608 | New | +$34.1M |
|
9
Insmed
INSM
$28.8B
| $29.1M | 3.86% | +2,433,319 | New | +$29.1M |
|
|
DSCI
10
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
| $26.6M | 3.53% | +1,994,876 | New | +$26.6M |
|
|
VIRX
11
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
| $24.5M | 3.24% | +4,716,296 | New | +$24.5M |
|
12
Xoma
XOMA
$392M
| $24.3M | 3.23% | +6,698,558 | New | +$24.3M |
|
|
HPTX
13
DELISTED
HYPERION THERAPEUTICS INC COM STK (DE)
HPTX
| $19.9M | 2.63% | +902,858 | New | +$19.9M |
|
|
RCPT
14
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
| $19.4M | 2.57% | +975,000 | New | +$19.4M |
|
15
Omeros
OMER
$283M
| $14.9M | 1.97% | +2,953,004 | New | +$14.9M |
|
16
Achieve Life Sciences
ACHV
$152M
| $8.46M | 1.12% | +863,332 | New | +$8.46M |
|
17
Enanta Pharmaceuticals
ENTA
$180M
| $7.72M | 1.02% | +436,145 | New | +$7.72M |
|
|
ENZ
18
DELISTED
Enzo Biochem, Inc.
ENZ
| $6.96M | 0.92% | +3,348,029 | New | +$6.96M |
|
19
Dynavax Technologies
DVAX
$1.19B
| $6.6M | 0.88% | +6,000,000 | New | +$6.6M |
|
20
Prothena Corp
PRTA
$441M
| $6.43M | 0.85% | +497,807 | New | +$6.43M |
|
21
Arrowhead Research
ARWR
$3.05B
| $6.23M | 0.83% | +3,114,755 | New | +$6.23M |
|
|
EPZM
22
DELISTED
Epizyme, Inc
EPZM
| $4.25M | 0.56% | +151,000 | New | +$4.25M |
|
|
SNMX
23
DELISTED
Senomyx, Inc.
SNMX
| $2.13M | 0.28% | +975,610 | New | +$2.13M |
|
|
OCRX
24
DELISTED
Ocera Therapeutics, Inc.
OCRX
| $1.27M | 0.17% | +2,700,000 | New | +$1.27M |
|